Status:
RECRUITING
Biomarkers of Inflammation and Fibrosis in Conduction Disorders After TAVI
Lead Sponsor:
Clinical Hospital Center Rijeka
Collaborating Sponsors:
University of Rijeka, Medical Faculty
Conditions:
TAVI(Transcatheter Aortic Valve Implantation)
Conduction Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant i...
Detailed Description
Transcatheter aortic valve implantation (TAVI) has become an established therapeutic option for the management of severe aortic stenosis (AS) in patients at all levels of surgical risk. Significant im...
Eligibility Criteria
Inclusion
- Written consent to participate in the trial
- Diagnosis of severe AS according to current European Society of Cardiology (ESC) guidelines for valvular heart disease
Exclusion
- Acute infectious disease
- Chronic inflammatory or autoimmune disease
- Corticosteroid or other immunosuppressive therapy
- Active malignant disease
- Liver disease accompanied by dysfunction
- Permanent pacemaker implanted previously
- An acute myocardial infarction within three months before the procedure
- A surgical procedure within three months before the procedure
- Previous surgical or transcatheter aortic valve replacement/implantation
- End-stage chronic kidney disease (eGFR \<15 ml/min)
Key Trial Info
Start Date :
December 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT07201363
Start Date
December 12 2024
End Date
August 1 2026
Last Update
October 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Hospital Center Rijeka
Rijeka, Croatia, Croatia, 51000